These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1085 related articles for article (PubMed ID: 28821363)

  • 1. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
    Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
    Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
    Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
    Latzke AB; Fernández P; Chiurchiu C; Sarmantano D; De Arteaga J; Douthat W; De la Fuente J
    Medicina (B Aires); 2018; 78(2):119-122. PubMed ID: 29659362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review.
    Fayek SA; Allam SR; Martinez E; Pan G; Dao A; Rofaiel G
    Transplant Proc; 2020; 52(1):146-152. PubMed ID: 31924403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
    Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
    PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience.
    Alpay N; Ozçelik U
    Transplant Proc; 2019 Sep; 51(7):2295-2297. PubMed ID: 31400975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 55.